Abrilada is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat rheumatoid arthritis (RA), as well as juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Abrilada is also known by its drug name, Adalimumab-afzb.
Abrilada is a tumor necrosis factor (TNF) blocker. It is believed to work by suppressing the inflammatory immune response brought about by the cell-signaling protein TNF, thereby reducing symptoms of rheumatoid arthritis and other immune-system diseases. Abrilada is biologically similar to the FDA-approved drug Humira (Adalimumab).
How do I take it?
Abrilada is taken as a subcutaneous injection every other week.
The FDA-approved label for Abrilada lists common side effects including infections (e.g., upper respiratory or sinus), injection site reactions, headache, and rash.
Rare but serious side effects can include advanced infections, such as tuberculosis and bacterial sepsis, as well as lymphoma and other malignancies in young adults and children.
For more details about this treatment, visit: